See more : Future First Technologies Ltd (FFT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectis S.A. (CLLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectis S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Watermark Lodging Trust, Inc. (WRMK) Income Statement Analysis – Financial Results
- Furukawa Electric Co., Ltd. (5801.T) Income Statement Analysis – Financial Results
- SJ Corporation Limited (SJCORP.BO) Income Statement Analysis – Financial Results
- Dongfang Electric Corporation Limited (600875.SS) Income Statement Analysis – Financial Results
- Hanma Technology Group Co.,Ltd. (600375.SS) Income Statement Analysis – Financial Results
Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M | 25.19M | 42.58M | 55.04M | 26.30M | 22.82M | 27.81M | 20.73M | 20.98M | 17.32M | 14.77M | 4.10M |
| Cost of Revenue | 737.00K | 1.77M | 36.28M | 36.28M | 11.39M | 2.74M | 2.62M | 1.69M | 2.71M | 3.69M | 847.86K | 2.03M | 3.26M | 1.92M | 2.33M | 1.54M | 1.48M |
| Gross Profit | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M | 22.57M | 40.90M | 52.34M | 22.61M | 21.97M | 25.78M | 17.47M | 19.06M | 14.99M | 13.23M | 2.62M |
| Gross Profit Ratio | 2.38% | 90.76% | 50.95% | 50.95% | 25.00% | 78.49% | 89.60% | 96.04% | 95.08% | 85.97% | 96.28% | 92.70% | 84.27% | 90.84% | 86.57% | 89.56% | 63.99% |
| Research & Development | 87.65M | 97.50M | 86.95M | 86.95M | 92.04M | 76.57M | 79.23M | 74.56M | 57.30M | 17.52M | 34.44M | 25.10M | 15.95M | 16.37M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.81M | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 0.00 | 0.00 | 0.00 | 7.97M | 5.70M | 4.28M |
| Selling & Marketing | 0.00 | 3.11M | 6.33M | 1.66M | 11.43M | 16.69M | 9.14M | 8.41M | 6.67M | 6.57M | 18.14M | 0.00 | 0.00 | 17.90M | 0.00 | 0.00 | 0.00 |
| SG&A | 16.81M | 17.49M | 44.20M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 25.83M | 26.69M | 17.90M | 7.97M | 5.70M | 4.28M |
| Other Expenses | -7.14M | -7.93M | -8.04M | -8.04M | -7.71M | -25.42M | -17.90M | -19.38M | -10.88M | -11.05M | -15.95M | 995.85K | 142.57K | 35.91K | 19.54M | 12.32M | 4.37K |
| Operating Expenses | 97.32M | 107.07M | 123.11M | 123.11M | 127.35M | 115.08M | 115.22M | 104.86M | 82.87M | 28.98M | 67.13M | 51.92M | 42.78M | 34.31M | 27.51M | 18.03M | 10.41M |
| Cost & Expenses | 98.06M | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M | 117.84M | 106.54M | 85.57M | 32.68M | 67.97M | 53.95M | 46.04M | 36.23M | 29.84M | 19.57M | 11.88M |
| Interest Income | 3.61M | 1.12M | 736.00K | 1.95M | 8.34M | 16.76M | 1.97M | 44.17K | 8.25M | 384.26K | 437.74K | 477.82K | 794.50K | 645.03K | 1.79M | 1.13M | 835.44K |
| Interest Expense | 6.43M | 3.79M | 5.34M | 12.05M | 2.61M | 46.00K | 4.00K | 6.31K | 22.96K | 195.78K | 407.36K | 2.32M | 632.49K | 203.48K | 8.60K | 13.92K | 29.16K |
| Depreciation & Amortization | 18.52M | 18.44M | 14.16M | 9.82M | 6.88M | 2.38M | 3.37M | 2.21M | 1.91M | 1.67M | 45.93M | 2.42M | 804.87K | 1.58M | 368.22K | 400.92K | 852.93K |
| EBITDA | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | -93.79M | -108.08M | -65.32M | -26.21M | 370.08K | 1.17M | -26.14M | -25.31M | -12.98M | -12.25M | -3.36M | -5.99M |
| EBITDA Ratio | -12,269.67% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -52.00% | -16.86% | 5.13% | -93.98% | -118.21% | -61.87% | -59.13% | -21.56% | -148.45% |
| Operating Income | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | -105.09M | -92.65M | -63.96M | -30.53M | -6.38M | -80.62M | -26.14M | -25.31M | -15.25M | -13.50M | -4.80M | -7.78M |
| Operating Income Ratio | -14,122.65% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -55.46% | -24.25% | -353.35% | -93.98% | -122.09% | -72.68% | -77.92% | -32.48% | -189.73% |
| Total Other Income/Expenses | -16.42M | -8.94M | 6.73M | -12.05M | 8.34M | 16.76M | -11.03M | 47.00K | 8.38M | 8.63M | -3.99M | -1.90M | 172.38K | 486.77K | 812.28K | 1.10M | 810.65K |
| Income Before Tax | -123.05M | -98.60M | -97.48M | -97.48M | -115.21M | -88.33M | -103.68M | -63.92M | -22.27M | 2.25M | -81.09M | -27.87M | -25.14M | -14.76M | -11.72M | -3.68M | -6.97M |
| Income Before Tax Ratio | -16,297.48% | -514.32% | -131.82% | -131.82% | -758.47% | -693.84% | -411.63% | -150.09% | -40.47% | 8.56% | -355.39% | -100.21% | -121.26% | -70.36% | -67.66% | -24.94% | -169.96% |
| Income Tax Expense | -6.21M | 87.00K | -11.20M | -24.91M | -24.53M | 16.81M | -13.20M | -1.54M | -926.03K | 2.42M | 4.68M | 1.58M | 5.76M | -4.04M | -6.20M | -3.87M | -2.61M |
| Net Income | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M | -78.69M | -99.37M | -63.92M | -22.46M | 24.32K | -84.28M | -29.45M | -30.90M | -10.72M | -5.52M | 185.15K | -4.36M |
| Net Income Ratio | -13,385.30% | -514.78% | -116.68% | -98.14% | -597.01% | -618.12% | -394.51% | -150.10% | -40.81% | 0.09% | -369.38% | -105.89% | -149.05% | -51.11% | -31.87% | 1.25% | -106.22% |
| EPS | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.81 | -0.66 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| EPS Diluted | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.78 | -0.65 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| Weighted Avg Shares Out | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.29M | 34.15M | 26.07M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
| Weighted Avg Shares Out (Dil) | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.81M | 34.52M | 26.19M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual...
Cellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 • Conference call and webcast scheduled for tomorrow, May 29, 2024...
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results...
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its...
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024...
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring novel...
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second...
Source: https://incomestatements.info
Category: Stock Reports